Sebastien Beauzile Is Pain-Free After Lyfgenia While a $3.1 Million Sickle Cell Therapy Still Barely Reaches Patients
New York's First: Long Island Patient Celebrates Freedom from Sickle Cell Disease with Breakthrough Gene Therapy
Sebastien Beauzile a un deuxième anniversaire qui ne figure sur aucun certificat de naissance. Il a choisi le 17 décembre 2024, l'après-midi les médecins du Cohen Children's Medical Center ont poussé un sac de ses propres cellules souches réécrites dans sa veine. Le jeune de 21 ans de Laurelton, Queens, qui a grandi à Long Island, avait passé la plupart des années avant cette date à mesurer la vie avec des scores de douleur. Le 13 mars 2025, le personnel de Northwell Health lui chantait sur un gâteau de velours rouge et appelait le jour une renaissance. Il leur a dit qu'il était inarrêtable. La phrase la plus dure est venue plus tard, dans des entretiens plus silencieux: il n'était plus dans la douleur.
L'Alliance AEGIS ne traite pas cette phrase comme un slogan. C'est une revendication clinique sur un seul corps, et il est assis à côté d'un registre national qui ne s'additionne toujours pas. Lyfgenia, la biothérapie de l'oiseau bleu vendu et que la société commercialise maintenant sous le nom de Genetix, se classe à environ 3,1 millions de dollars avant le séjour à l'hôpital. Casgevy, le rival CRISPR de Vertex et CRISPR Therapeutics, compte près de 2,2 millions de dollars. Aux États - Unis, environ 100 000 personnes vivent avec une drépanocytose. Une présentation scientifique liée à l'American Society of Hématology a mis le nombre de patients effectivement infusés avec Lyfgenia à moins de 40. Dans l'ensemble de la Lyfgénie et du produit de bêta-thalassémie Zynteglo, la même équipe a indiqué que 312 patients avaient été recrutés et 77, environ un quart, avaient reçu des cellules modifiées. Un remède qui fonctionne dans une conférence de presse et un remède qui atteint un recensement ne sont pas le même produit.
A childhood spent on the same corridor
La drépanocytose est une erreur d'une seule lettre dans l'hémoglobine. Les globules rouges qui doivent rester ronds et flexibles s'effondrent dans les croissants, embâclent les petits vaisseaux et affaissent les tissus d'oxygène. Le résultat est la douleur vaso-occlusive, accident vasculaire cérébral, lésions des organes, et une vie qui est souvent plus courte qu'elle ne devrait l'être. Aux États-Unis, la mutation touche plus durement les familles noires. Environ 1 bébé noir ou afro-américain sur 365 naît avec la maladie. La version de Beauzile était assez sévère que Cohen Children le connaissait depuis qu'il avait deux mois.
« I was basically in and out of the hospital, » he told the New York Post. « I believe I spent more time in the hospital than I did at home. » A crisis, he said, took movement itself away. « You can’t walk. You can’t move. You can’t do anything. » His mother, Magda Lamour, told CBS New York there were not enough words for what the staff had done. Dr. Jeffrey Lipton, who leads pediatric hematology and stem cell transplant at Cohen, put the calendar in a longer frame. Sickle cell disease was described in modern medicine in 1910, he said, and more than a century later this was the first cure the room was looking at. « The patient is their drug, » Lipton said, because the medicine is the patient’s own marrow.
What the infusion actually changes
Lyfgenia, lovotibeglogene autotemcel, is not a CRISPR snip. Technicians collect hematopoietic stem cells, then use a disabled lentivirus to insert a working hemoglobin gene. The cells are instructed to make HbAT87Q, a hemoglobin built to resist sickling. The patient takes busulfan chemotherapy so the old marrow steps aside. The modified cells go back by intravenous line. If they engraft, the blood that follows does not collapse the same way. The Food and Drug Administration approved the product in December 2023 for patients 12 and older with a history of vaso-occlusive events, the same month it approved Casgevy.
The label carries a boxed warning. Two people treated with an earlier version of the platform later developed acute myeloid leukemia. Recipients are told to stay in cancer surveillance for life. Busulfan can also end fertility, which means the counseling happens before anyone celebrates a re-birthday. Cohen Children’s was the first hospital in New York State to give the commercial product. Dr. Banu Aygun, Beauzile’s hematologist, and Dr. Jon Fish had followed him for years. He has described the time since the December infusion as free of the crises that used to own the calendar. « Sickle cell was like a blockade for me, » he told CBS, « but now it’s just like a wall that I just jumped over. »
A map of firsts, and a factory that is still small
Beauzile is New York’s first commercial Lyfgenia patient, not the first person the science has ever freed. Twelve-year-old Kendric Cromer, in the Washington suburbs, became the first patient anywhere to start a commercially approved sickle cell gene therapy after the FDA green light, beginning cell collection in 2024. Victoria Gray had already shown, in a CRISPR trial that began in 2019, that raising fetal hemoglobin could shut the disease down. The map has kept adding pins. Chantez Sanford Jr., 24, became the first person in Michigan to receive Lyfgenia at Children’s Hospital of Michigan. In January 2026, Los Angeles teenager Yasmin Mbeyu became the fourth patient of any age at UCLA Health to be infused, went home in February, and by late summer had not needed a transfusion since May. In June 2026, 23-year-old Daniel Cressy rang a bell at Manning Family Children’s in New Orleans after Casgevy and called the result Life 2, the first such infusion in Louisiana and the Gulf South.
Those pins are real. They are also sparse. A Boston Globe account in July 2026 described bluebird’s distressed sale and rebrand as Genetix, and quoted the new ownership saying the company had treated over 100 patients in the United States the prior year while Vertex had treated 64 worldwide. Outside hematologists told the Globe the comparison was easy to overstate, and that cell collection has been difficult for Lyfgenia too. Only about a fifth of Americans with sickle cell disease are thought to be realistic candidates, because the chemotherapy step can kill. Genetix has said it wants to be treating 1,000 patients a year by 2030. Wanting that number and having the beds are different jobs.
Who is supposed to pay the invoice
Medicaid covers roughly half of Americans with sickle cell disease. A $3.1 million list price is not a line item a state can absorb one patient at a time without a fight. The Centers for Medicare and Medicaid Services built a Cell and Gene Therapy Access Model that lets states buy these products together and claw money back if the therapy fails. The Biden administration signed the manufacturer deals in December 2024. The Trump administration kept the model. In a July 2025 statement, CMS administrator Mehmet Oz called it a game changer and announced that 33 states, the District of Columbia, and Puerto Rico had joined, a group covering about 84 percent of Medicaid beneficiaries with the disease. The contract terms are confidential. A spokesperson told reporters they had been disclosed only to state Medicaid agencies. Outcomes-based payment is a theory until a family can see what « did not work » means on a denial letter.
New York is also trying to build the machines, not only the patients. Governor Kathy Hochul and Northwell have tied a cell and gene therapy campus in Lake Success, branded New York Biogenesis Park, to state support that can reach $150 million. The New York Blood Center ran the three collection sessions that made Beauzile’s dose. That unglamorous step is the part of the procedure that does not photograph well.
Ordinary weather, extraordinary surveillance
Beauzile’s new life is made of small permissions. He can hike. He can work out. He can stand in cold air. « I don’t have to worry about getting sick from the cold, » he told PIX11. « I’ve been going outside in the cold, and I’ve been fine. » Travel is no longer a calculation about the nearest emergency room. He has talked about school and about working in medicine, which is a reasonable thing to want after a childhood spent as the case study.
The surveillance does not end because the pain did. Doctors will watch his blood for malignant clones for the rest of his life. Some New Yorkers already in workups at the same Northwell program will be offered Casgevy instead. Some will be told their organs are too damaged, or that they cannot survive the chemotherapy that makes room for the new cells. Readers who follow medical firsts on our health desk have seen the same split in a titanium heart that carried an Australian man to a donor organ and in a fungal compound finally synthesized for childhood brain tumors. Proof in one body is not a delivery system.
For one 21-year-old, the blockade is behind him. The waiting list is not. Factories in Lake Success, confidential Medicaid contracts, and a health system that underfunded this mutation for a century will decide whether his re-birthday stays a headline or becomes a procedure. More of this reporting lives in U.S. news et sciences coverage from The AEGIS Alliance.
